Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

507.60INR
6:29am EDT
Change (% chg)

Rs1.65 (+0.33%)
Prev Close
Rs505.95
Open
Rs506.00
Day's High
Rs515.00
Day's Low
Rs505.15
Volume
3,615,167
Avg. Vol
5,760,131
52-wk High
Rs784.25
52-wk Low
Rs432.70

Latest Key Developments (Source: Significant Developments)

Sun Pharma, NIV in pact to test biologic, chemical entities against zika,chikungunya, dengue
Monday, 26 Jun 2017 10:40pm EDT 

June 27 (Reuters) - Sun Pharmaceutical Industries Ltd ::Sun Pharma & NIV sign agreement to fight zika, chikungunya and dengue.Signed agreement for testing phytopharmaceutical, biologic, chemical entities developed by co against zika, chikungunya, dengue viruses.Sun Pharma will provide drug molecules to NIV for testing against zika, chikungunya and dengue in model systems.Candidate molecules with encouraging data will then be taken forward for commercial development.Patients are given symptomatic treatment.  Full Article

Sun Pharmaceutical Industries exec says co expects to be able to address Halol issues over next few qtrs
Tuesday, 14 Feb 2017 08:29am EST 

Sun Pharmaceutical Industries Ltd : Exec says expects to be able to address Halol issues over the next few quarters . Exec says continues to update FDA on remediation progress at Halol plant . Exec says to focus on improving supply and improving market share in United States . Exec says base business continues to have challenges related to pricing Further company coverage: [SUN.NS] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sun Pharmaceutical Industries Q3 India sales up by 5 pct
Tuesday, 14 Feb 2017 05:32am EST 

Sun Pharmaceutical Industries Ltd : Says Q3 india sales at inr 19.69 billion, up by 5% over q3 last year .Sales in US were us$ 507 million for quarter, up 4% over same period last year and accounted for 45% of total sales..  Full Article

Sun Pharmaceutical Dec-qtr consol profit down about 5 pct
Tuesday, 14 Feb 2017 04:50am EST 

Sun Pharmaceutical Industries Ltd : Dec quarter consol net profit 14.72 billion rupees . Dec quarter consol total income from operations 79.13 billion rupees . consensus forecast for Dec quarter consol profit was 17.83 billion rupees .consol net profit in Dec quarter last year was 15.45 billion rupees as per ind-as; consol total income from operations was 71.22 billion rupees.  Full Article

Sun Pharma, Moebius Medical sign licensing deal to develop pain drug
Monday, 12 Dec 2016 06:09am EST 

Sun Pharmaceutical Industries Ltd : Sun Pharma & Moebius Medical sign exclusive global licensing deal . Deal to develop novel liposomal non-opiod pain product for osteoarthritis . Moebius medical will get upfront payment, development-based,sales-based milestone payments, tiered royalties on sales from co . To fund further development of MM-II . Sun Pharma has worldwide commercialization & manufacturing rights . Moebius Medical will conduct requisite pre-clinical studies .Moebius medical will assume responsibility for product development and manufacturing through the end of phase-ii studies.  Full Article

Beijing Science Sun Pharmaceutical unit to pay penalty of 0.3 mln yuan
Friday, 19 Aug 2016 04:05am EDT 

Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ>: Says its unit received report of administrative punishment from environmental protection department .Says the unit was ordered to pay penalty of about 0.3 million yuan regarding its wastewater discharge.  Full Article

Sun Pharmaceutical Industries June-qtr consol profit rises almost fourfold
Friday, 12 Aug 2016 04:46am EDT 

Sun Pharmaceutical Industries Ltd : June-quarter consol net profit 20.34 billion rupees . June-quarter consol total income from operations 82.43 billion rupees . June-quarter net profit consensus forecast was 19.04 billion rupees . Consol net profit in June-quarter last year was 5.56 billion rupees as per Ind-AS; consol net sales was 67.61 billion rupees .  Full Article

Sun Pharmaceutical extends Imatinib Mesylate Savings Card program benefits for patients in USA
Monday, 8 Aug 2016 08:32am EDT 

Sun Pharmaceutical Industries Ltd : Sun Pharma extends Imatinib Mesylate Savings Card program benefits for patients in USA . Co will continue to offer up to US$ 700 reduction on each eligible patient's initial out-of-pocket cost from their commercial insurer . Benefit will cover a patient's monthly fills for a 30-day supply of Sun pharma's imatinib mesylate prescribed for ph+cml, . Will also continue hub service wherein patients can call and speak with a trained healthcare professional .  Full Article

India's Sun Pharma gets FDA nod for generic Glumetza
Monday, 1 Aug 2016 11:44pm EDT 

Sun Pharmaceutical Industries Ltd : Sun Pharma announces U.S. FDA approval for generic Glumetza . The commercial launch of the tablets in the U.S. is expected over the next few weeks .  Full Article

Sun Pharma and Almirall signs license deal for Psoriasis treatment
Wednesday, 27 Jul 2016 10:32pm EDT 

Sun Pharmaceutical Industries Ltd : Almirall and Sun Pharma enter into a license agreement for Tildrakizumab in Europe for Psoriasis . To receive development & regulatory milestone payments, royalties, the terms of which are confidential .  Full Article

BRIEF-Sun Pharmaceutical Industries gets shareholders' nod for re-appointing Dilip Shangvhi as MD

* Gets shareholders' nod for re-appointment of Dilip Shangvhi as MD Source text: http://bit.ly/2hsHpyV Further company coverage: